INT94163

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 14
Disease Relevance 6.86
Pain Relevance 1.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (UCN2) extracellular space (UCN2) extracellular region (UCN2)
response to stress (UCN2)
UCN2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C inhibitor 1 100.00 Very High Very High Very High
antagonist 11 99.96 Very High Very High Very High
intrathecal 6 99.84 Very High Very High Very High
agonist 1 94.40 High High
Pain 12 93.20 High High
gABA 2 92.56 High High
Inflammation 39 90.32 High High
Action potential 2 76.44 Quite High
GABAergic 4 75.00 Quite High
spinal dorsal horn 1 73.12 Quite High
Disease Link Frequency Relevance Heat
Chronic Periodontitis 71 99.54 Very High Very High Very High
Mantle-cell Lymphoma 1 94.88 High High
Pain 12 93.20 High High
Pressure Volume 2 Under Development 2 93.08 High High
Diarrhoea 2 92.44 High High
Apoptosis 4 92.32 High High
Stomach Cancer 2 91.12 High High
Nicotine Addiction 46 90.88 High High
Syndrome 1 90.68 High High
INFLAMMATION 43 90.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
During periodontal probing and SRP, VAS scores decreased with increasing age for two procedures (Spearman rho, -0.301 and -0.348, respectively; P < 0.01).
Negative_regulation (decreased) of SRP
1) Confidence 0.57 Published 2007 Journal Clin Oral Investig Section Abstract Doc Link 17576606 Disease Relevance 0.70 Pain Relevance 0.36
CONCLUSIONS: LDS is more effective than BGP for topical pain suppression to Ns and SRP in both arches.


Negative_regulation (suppression) of SRP
2) Confidence 0.42 Published 2001 Journal J. Periodontol. Section Body Doc Link 11338300 Disease Relevance 0.11 Pain Relevance 0
Intrathecal NMDA (100 microM, 10 microl) reversed the abolition on SRP caused by anal stretch.
Negative_regulation (reversed) of SRP associated with intrathecal
3) Confidence 0.42 Published 2008 Journal Am. J. Physiol. Renal Physiol. Section Abstract Doc Link 18632795 Disease Relevance 0.34 Pain Relevance 0.42
Acute anal stretch using a mosquito clamp with a distance of 4 mm exhibited no effect, whereas distances of 8 mm attenuated and 12 mm abolished the repetitive stimulation-induced SRP.
Negative_regulation (abolished) of SRP
4) Confidence 0.42 Published 2008 Journal Am. J. Physiol. Renal Physiol. Section Abstract Doc Link 18632795 Disease Relevance 0.33 Pain Relevance 0.41
Intrathecal SB-408124 (10 muM, 10 mul), an OX-1 antagonist, reversed the abolition on SRP caused by OxA.
Negative_regulation (reversed) of SRP associated with antagonist and intrathecal
5) Confidence 0.41 Published 2008 Journal Am. J. Physiol. Endocrinol. Metab. Section Abstract Doc Link 18477704 Disease Relevance 0.19 Pain Relevance 0.34
The second cdk modulator tested in clinical trials, UCN-01, is a PKC inhibitor that can also modulate cdk activity.
Negative_regulation (inhibitor) of UCN-01
6) Confidence 0.21 Published 2000 Journal Oncogene Section Abstract Doc Link 11426645 Disease Relevance 1.27 Pain Relevance 0.07
The second cdk modulator tested in clinical trials, UCN-01, is a potent protein kinase C inhibitor that inhibits cdk activity in vitro as well.
Negative_regulation (inhibitor) of UCN-01 associated with kinase c inhibitor
7) Confidence 0.18 Published 2001 Journal Leukemia Section Abstract Doc Link 11243375 Disease Relevance 1.48 Pain Relevance 0.15
Its mean value 4.27 (±1.61) is significantly higher compared to the threshold obtained in the isotropic sample (2.28 ±0.67) (p<0.01), therefore suggesting anisotropy to be linked to a global impairment of SRP.
Negative_regulation (impairment) of SRP
8) Confidence 0.15 Published 2010 Journal The Open Ophthalmology Journal Section Body Doc Link PMC2928889 Disease Relevance 0 Pain Relevance 0
Thereby, effectiveness of SRP and AF may be analyzed across the limits of indications as the ranges of PPD for the three treatment groups in Table 4 demonstrate.
Negative_regulation (effectiveness) of SRP
9) Confidence 0.13 Published 2007 Journal Clin Oral Investig Section Body Doc Link PMC2134843 Disease Relevance 0.11 Pain Relevance 0
This is quite similar to the results of this study regarding PAL-V gain and PPD reduction after SRP.
Negative_regulation (reduction) of SRP
10) Confidence 0.12 Published 2007 Journal Clin Oral Investig Section Body Doc Link PMC2134843 Disease Relevance 0.55 Pain Relevance 0
The SOD activity in both groups showed a similar profile, a decrease until one month after SRP and an increase after 3 months.
Negative_regulation (decrease) of SRP
11) Confidence 0.02 Published 2010 Journal Journal of Periodontal & Implant Science Section Body Doc Link PMC2931304 Disease Relevance 0.84 Pain Relevance 0
In the test group, the TAS decreased directly after SRP.
Negative_regulation (decreased) of SRP
12) Confidence 0.02 Published 2010 Journal Journal of Periodontal & Implant Science Section Abstract Doc Link PMC2931304 Disease Relevance 0.24 Pain Relevance 0
SOD activity in the severe chronic periodontitis patients and controls decreased immediately after SRP until 1 month but had increased again at 3 months.
Negative_regulation (decreased) of SRP associated with chronic periodontitis
13) Confidence 0.02 Published 2010 Journal Journal of Periodontal & Implant Science Section Body Doc Link PMC2931304 Disease Relevance 0.17 Pain Relevance 0
The SOD activity in the test and control subjects decreased immediately after SRP until 1 month.
Negative_regulation (decreased) of SRP
14) Confidence 0.02 Published 2010 Journal Journal of Periodontal & Implant Science Section Abstract Doc Link PMC2931304 Disease Relevance 0.52 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox